Arbutus Biopharma Corporation
ABUS
$4.58
$0.173.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 10,054.54% | -33.23% | -60.49% | 522.19% | 15.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10,054.54% | -33.23% | -60.49% | 522.19% | 15.14% |
| Cost of Revenue | -54.01% | -43.18% | -59.52% | -64.65% | -41.84% |
| Gross Profit | 2,532.33% | 45.34% | 59.42% | 137.91% | 48.13% |
| SG&A Expenses | 0.98% | -21.71% | -32.91% | -55.90% | 9.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.33% | -35.70% | -53.10% | -61.79% | -28.60% |
| Operating Income | 1,398.20% | 36.02% | 52.53% | 108.95% | 32.09% |
| Income Before Tax | 791.90% | 70.03% | 60.73% | 112.74% | -37.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 791.90% | 70.03% | 60.73% | 112.74% | -37.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 791.90% | 70.03% | 60.73% | 112.74% | -37.21% |
| EBIT | 1,398.20% | 36.02% | 52.53% | 108.95% | 32.09% |
| EBITDA | 1,432.03% | 34.28% | 51.67% | 109.15% | 32.56% |
| EPS Basic | 781.03% | 70.50% | 61.27% | 112.54% | -26.33% |
| Normalized Basic EPS | 1,512.37% | 36.60% | 53.93% | 114.75% | 38.41% |
| EPS Diluted | 769.23% | 70.50% | 61.27% | 109.09% | -27.70% |
| Normalized Diluted EPS | 1,502.06% | 36.60% | 53.93% | 114.75% | 38.41% |
| Average Basic Shares Outstanding | 1.61% | 1.40% | 1.47% | 1.87% | 8.59% |
| Average Diluted Shares Outstanding | 2.36% | 1.40% | 1.47% | 2.32% | 8.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |